Efforts should focus on optimizing tracers distinguishing between established biomarkers, such as HER2 and ERα, and developing emerging targets, like ERβ and HER4, to better capture the molecular heterogeneity of breast cancer. This evidence concerns the gene ERBB2 and breast cancer.